Iron and atherosclerosis: Inhibition by the iron chelator deferiprone (L1)1

Journal of Surgical Research

Volumn 73, Issue 1, 1997, Pages 35-40

  Matthews, Andrew J ^a   Vercellotti, Gregory M ^a   Menchaca, Hector J ^a   Bloch, Paul H S ^a   Michalek, Van N ^a   Marker, Paul H ^a   Murar, Jozef ^a   Buchwald, Henry ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Atherosclerosis; Iron; Oxidation

Indexed keywords

DEFERIPRONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROSCLEROSIS; DRUG EFFECT; HUMAN; HUMAN CELL; IRON CHELATION; LIPID PEROXIDATION; NONHUMAN; PRIORITY JOURNAL; RABBIT; UMBILICAL VEIN; VASCULAR ENDOTHELIUM;

EID: 0031277617     PISSN: 00224804     EISSN: None     Source Type: Journal    
DOI: 10.1006/jsre.1997.5180     Document Type: Article

References (36)

1. 1. Steinberg, D., Parthasarathy, S., Carew, T. E., Khoo, J. C., and Witzum, J. L. Beyond cholesterol. N. Engl. J. Med. 320: 915-924, 1989.
2. 2. Balla, G., Jacob, H. S., Eaton, J. W., Belcher, J. D., and Vercellotti, G. M. Hemin: A physiological mediator of low density lipoprotein oxidation and endothelial injury. Arterioscler. Thromb. 11: 1700-1711, 1991.
3. 3. Salonen, J. T., Nyyssonen, K., Korpela, H., Tuomilehto, J., Seppanen, R., and Salonen, R. High stored iron levels are associated with excess risk of myocardial infarction in Eastern Finnish men. Circulation. 86: 803-811, 1992.
4. 4. Salonen, J. T., Nyyssonen, K., and Salonen, R. Body iron stores and the risk of coronary heart disease. N. Engl. J. Med. 331: 1159, 1994.
5. 5. Araujo, J. A., Romano, E. L., Brito, B. E., Parthé, V., Romano, M., Bracho, M., Montaño, R. F., and Cardier, J. Iron overload augments the development of atherosclerotic lesions in rabbits. Arterioscler. Thromb. Vasc. Biol. 15: 1172-1180, 1995.
6. 6. Olivieri, N. F., Koren, G., Matsui, D., Liu, P. P., Blendis, L., Cameron, R., McClellan, R. A., and Templeton, D. M. Reduction in iron stores and normalization of serum ferritin concentration during treatment with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in thalassemia intermedia. Blood 79: 2741, 1992.
7. 7. Kontoghiorghes, G. J. Design, properties, and effective use of the oral chelator L1 and other alpha-ketohydroxypyridine in the treatment of transfusional iron overload in thalassemia. Ann. N.Y. Acad. Sci. 612: 339-350, 1990.
8. 8. Belcher, J., Balla, G., Balla, J., Jacobs, D. R., Gross, M., Jacob, H. S., and Vercellotti, G. M. Vitamin E, LDL and endothelium: Brief oral vitamin supplementation prevents oxidized LDL-mediated vascular injury in vitro. Arterioscler. Thromb. 13: 1779-1789, 1993.
9. 9. Jaffe, E. A., Nachman, R. L., Becker, C. G., and Minick, C. R. Culture of human endothelial cells derived from umbilical veins: Identification of morphological criteria. J. Clin. Invest. 52: 2745-2756, 1973.
10. 10. Forti, R. L., Schuffman, S. S., Davies, H. A., and Mitchell, W. M. Objective antiviral assay of the interferons by computer assisted data collection and analysis. Methods Enzymol. 119: 533-540, 1986.
11. 11. Bronzert, T. J., and Brewer, H. B. New micromethod for measuring cholesterol in plasma lipoprotein fractions. J. Clin. Chem. 23: 2089-2098, 1977.
12. 12. Allain, C. A., Poon, L. S., Chan, C. S. G., Richmond, W., and Fu, P. C. Enzymatic determination of total serum cholesterol. J. Clin. Chem. 20: 470-475, 1974.
13. 13. Buchwald, H. Myocardial infarction in rabbits induced solely by a hypercholesterolemic diet. J. Atheroscler. Res. 4: 407-419, 1965.
14. 14. Abell, L. L., Levy, B. B., Brodie, B. B., and Kendall, F. E. Simplified method for estimation of total cholesterol in serum and demonstration of its specificity. J. Biol. Chem. 195: 357-366, 1952.
15. 15. Clarkson, T. B., Lehner, N. D. M., and Wagner, W. D. A study of atherosclerosis regression in Macaca mulatta. I. design of experiment and lesion induction. Exp. Mol. Pathol. 30: 360-385, 1979.
16. 16. Sullivan, J. L. Iron and the sex difference in heart disease risk. Lancet 1: 1293-1294, 1981.
17. 17. Salonen, J. T. The role of iron as a cardiovascular risk factor. Curr. Opin. Lipidol. 4: 277-282, 1993.
18. 18. Ascherio, A., Willett, W. C., Rimm, E. B., Giovannucci, E. L., and Stampfer, M. J. Dietary iron intake and risk of coronary disease among men. Circulation 89: 969-974, 1994.
19. 19. Morrison, H. I., Semenciw, R. M., Mao, Y., and Wigle, D. T. Serum iron and risk of fatal acute myocardial infarction. Epidemiology 5: 243-246, 1994.
20. 20. Magnusson, M. K., Sigfusson, N., Sigvaldason, S., Johannesson, G. M., Magnusson, S., and Thorgeirsson, G. Low iron-binding capacity as a risk factor for myocardial infarction. Circulation 89: 102-108, 1994.
21. 21. Stampfer, M. J., Grodstein, F., Rosenberg, I., Willett, W., and Hennekens, C. A prospective study of plasma ferritin and risk of myocardial infarction in US physicians. Circulation 87: 688, 1993. [Abstract]
22. 22. Sempos, C. T., Looker, A. C., Gillum, R. F., and Makuc, D. M. Body iron stores and the risk of coronary heart disease. N. Engl. J. Med. 330: 1119-1124, 1994.
23. 23. Liao, Y., Cooper, R. S., and McGee, D. L. Iron status and coronary heart disease: Negative findings from the NHANES 1 epidemiologic follow-up study. Am. J. Epidemiol. 139: 704-712, 1994.
24. 24. Takkunen, H., Reunanen, A., Knekt, P., and Aromaa, A. Body iron stores and the risk of cancer. N. Engl. J. Med. 320: 1013-1014, 1989.
25. 25. Biemond, P., van Eijk, H. G., Swaak, J. G., and Koster, J. F. Iron mobilization from ferritin by superoxide derived from stimulated polymorphonuclear leukocytes. J. Clin. Invest. 73: 1576-1579, 1984.
26. 26. Bolann, B. J., and Ulvik, R. J. On the ability of superoxide to release iron from ferritin. Eur. J. Biochem. 193: 899-904, 1990.
27. 27. Puppo, A., and Halliwell, B. Formation of hydroxyl radicals from hydrogen peroxide in the presence of iron. Biochem. J. 249: 185-190, 1988.
28. 28. Gutteridge, J. M. C. Iron promoters of the Fenton reaction and lipid peroxidation can be released from haemoglobin by peroxides. FEBS Lett. 201: 291-295, 1986.
29. 29. Balla, G., Vercellotti, G. M., Muller-Eberhard, U., Eaton, J., and Jacob, H. S. Exposure of endothelial cells to free heme potentiates damage mediated by granulocytes and toxic oxygen species. Lab. Invest. 64: 648-655, 1991.
30. 30. Balla, G., Jacob, H. S., Balla, J., Rosenberg, M., Nath, K., Apple, F., Eaton, J. W., and Vercellotti, G. M. Ferritin: A cytoprotective strategem of endothelium. J. Biol. Chem. 267: 18148-18153, 1992.
31. 31. Juckett, M. B., Balla, J., Balla, G., Jessurun, J., Jacob, H. S., and Vercellotti, G. M. Ferritin protects endothelial cells from oxidized low density lipoprotein in vitro. Am. J. Pathol. 147: 782-789, 1995.
32. 32. Swain, J., and Gutteridge, J. M. C. Prooxidant iron and copper, with ferroxidase and xanthine oxidase activities in human atherosclerotic material. FEBS Lett. 368: 513-515, 1995.
33. 33. Smith, C., Mitchinson, M. J., Aruoma, O. I., and Halliwell, B. Stimulation of lipid peroxidation and hydroxyl-radical generation by the contents of human atherosclerotic lesions. Biochem. J. 286: 901-905, 1992.
34. 34. Brittenham, G. M. Development of iron-chelating agents for clinical use. Blood 80: 569-574, 1992.
35. 35. Sadrzadeh, S. M. H., Nanji, A. A., and Price, P. L. The oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one reduces hepatic-free iron, lipid peroxidation and fat accumulation in chronically ethanol-fed rats. J. Pharmacol. Exp. Ther. 269: 632-636, 1994.
36. 36. Barradas, M. A., Jeremy, J. Y., Kontoghiorghes, G. J., Mikhailidis, D. P., Hoffbrand, A. V., and Dandona, P. Iron chelators inhibit human platelet aggregation, thromboxane A2 synthesis and lipoxygenase activity. FEBS Lett. 245: 105-109, 1989.